MapLight Therapeutics shares are trading higher after Canaccord Genuity initiated coverage on the stock with a Buy rating and announced a $35 price target.

Benzinga Newsdesk www.benzinga.com Positive 94.5%

Neg 0% Neu 0% Pos 94.5%

Comments

No comments yet. Be the first!